Vitamin D and Chronic Diseases
Vitamin D and Chronic Diseases
Vitamin D is one of the essential nutrients to sustain the human health. As a member of the steroid hormone family, it has a classic role in regulating metabolism of calcium and a non-classic role in affecting cell proliferation and differentiation. Epidemiological studies have shown that 25OHD deficiency is closely associated with common chronic diseases such as bone metabolic disorders, tumors, cardiovascular diseases, and diabetes. 25OHD deficiency is also a risk factor for neuropsychiatric disorders and autoimmune diseases. 25OHD deficiency is highly prevalent in the world. It is therefore necessary to know the adverse health effects of 25OHD deficiency, and to design interventions and early treatments for those who are likely to have low levels of 25OHD.
Vitamin D / chronic diseases / early prevention / deficiency {{custom_keyword}} /
[1] |
Holick MF (2004). Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr, 80: 1678s-1688s
{{custom_citation.content}}
|
[2] |
Mathieu C, Badenhoop K (2005). Vitamin D and type 1 diabetes mellitus: state of the art. Trends Endocrinol Metab, 16: 261-266
{{custom_citation.content}}
|
[3] |
Misra M, Pacaud D, Petryk A, Collett-Solberg PF, Kappy M (2008). Vitamin D deficiency in children and its management: review of current knowledge and recommendations. Pediatrics, 122: 398-417
{{custom_citation.content}}
|
[4] |
Handono K, Sidarta YO, Pradana BA, Nugroho RA, Hartono IA, Kalim H, et al. (2014). Vitamin D prevents endothelial damage induced by increased neutrophil extracellular traps formation in patients with systemic lupus erythematosus. Acta Med Indones, 46: 189-198
{{custom_citation.content}}
|
[5] |
(2015). Correction: Treatment with Vitamin D/MOG Association Suppresses Experimental Autoimmune Encephalomyelitis. PLoS One, 10: e0131260
{{custom_citation.content}}
|
[6] |
Van Belle TL, Vanherwegen AS, Feyaerts D, De Clercq P, Verstuyf A, Korf H, et al. (2014). 1,25-Dihydroxyvitamin D3 and its analog TX527 promote a stable regulatory T cell phenotype in T cells from type 1 diabetes patients. PLoS One, 9: e109194
{{custom_citation.content}}
|
[7] |
Reddy KK (2013). Reply to Glossmann: vitamin D compounds and oral supplementation methods. J Invest Dermatol, 133: 2649
{{custom_citation.content}}
|
[8] |
Takahashi H, Hatta Y, Iriyama N, Hasegawa Y, Uchida H, Nakagawa M, et al. (2014). Induced differentiation of human myeloid leukemia cells into M2 macrophages by combined treatment with retinoic acid and 1alpha,25-dihydroxyvitamin D3. PLoS One, 9: e113722
{{custom_citation.content}}
|
[9] |
Zhang Z, Zhang H, Hu Z, Wang P, Wan J, Li B (2014). Synergy of 1,25-dihydroxyvitamin D3 and carboplatin in growth suppression of SKOV-3 cells. Oncol Lett, 8: 1348-1354
{{custom_citation.content}}
|
[10] |
Henry HL (2011). Regulation of vitamin D metabolism. Best Pract Res Clin Endocrinol Metab, 25: 531-541
{{custom_citation.content}}
|
[11] |
Hossein-nezhad A, Holick MF (2013). Vitamin D for health: a global perspective. Mayo Clin Proc, 88: 720-755
{{custom_citation.content}}
|
[12] |
Cantorna MT, Zhu Y, Froicu M, Wittke A (2004). Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. Am J Clin Nutr, 80: 1717s-1720s
{{custom_citation.content}}
|
[13] |
Ahmed SZ, Jaleel A, Hameed K, Qazi S, Suleman A (2015). DOES VITAMIN D DEFICIENCY CONTRIBUTE TO THE SEVERITY OF ASTHMA IN CHILDREN AND ADULTS? J Ayub Med Coll Abbottabad, 27: 458-463
{{custom_citation.content}}
|
[14] |
Holick MF (2007). Vitamin D deficiency. N Engl J Med, 357: 266-281
{{custom_citation.content}}
|
[15] |
Hossein-nezhad A, Holick MF (2012). Optimize dietary intake of vitamin D: an epigenetic perspective. Curr Opin Clin Nutr Metab Care, 15: 567-579
{{custom_citation.content}}
|
[16] |
Holick MF (2012). Vitamin D: extraskeletal health. Rheum Dis Clin North Am, 38: 141-160
{{custom_citation.content}}
|
[17] |
Kim SH, Choi GS, Nam YH, Kim JH, Hur GY, Kim SH, et al. (2012). Role of vitamin D-binding protein in isocyanate-induced occupational asthma. Exp Mol Med, 44: 319-329
{{custom_citation.content}}
|
[18] |
Safadi FF, Thornton P, Magiera H, Hollis BW, Gentile M, Haddad JG, et al. (1999). Osteopathy and resistance to vitamin D toxicity in mice null for vitamin D binding protein. J Clin Invest, 103: 239-251
{{custom_citation.content}}
|
[19] |
Taes YE, Goemaere S, Huang G, Van Pottelbergh I, De Bacquer D, Verhasselt B, et al. (2006). Vitamin D binding protein, bone status and body composition in community-dwelling elderly men. Bone, 38: 701-707
{{custom_citation.content}}
|
[20] |
Weinstein SJ, Purdue MP, Smith-Warner SA, Mondul AM, Black A, Ahn J, et al. (2015). Serum 25-hydroxyvitamin D, vitamin D binding protein and risk of colorectal cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Int J Cancer, 136: E654-664
{{custom_citation.content}}
|
[21] |
Hou JC, Min L, Pessin JE (2009). Insulin granule biogenesis, trafficking and exocytosis. Vitam Horm, 80: 473-506
{{custom_citation.content}}
|
[22] |
Johnson JA, Grande JP, Roche PC, Kumar R (1994). Immunohistochemical localization of the 1,25(OH)2D3 receptor and calbindin D28k in human and rat pancreas. Am J Physiol, 267: E356-360
{{custom_citation.content}}
|
[23] |
Dunlop TW, Vaisanen S, Frank C, Molnar F, Sinkkonen L, Carlberg C (2005). The human peroxisome proliferator-activated receptor delta gene is a primary target of 1alpha,25-dihydroxyvitamin D3 and its nuclear receptor. J Mol Biol, 349: 248-260
{{custom_citation.content}}
|
[24] |
Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R (2005). Estimates of optimal vitamin D status. Osteoporos Int, 16: 713-716
{{custom_citation.content}}
|
[25] |
Chen W, Zhang X, Wang H, Zhang W, Xu Y, Zheng S (2015). The epidemic investigation of serum 25-hydroxy vitamin D levels in the adults in Qujing area of Yunnan province in China. Int J Clin Exp Pathol, 8: 9597-9601
{{custom_citation.content}}
|
[26] |
Looker AC, Johnson CL, Lacher DA, Pfeiffer CM, Schleicher RL, Sempos CT (2011). Vitamin D status: United States, 2001-2006. NCHS Data Brief: 1-8
{{custom_citation.content}}
|
[27] |
Ginde AA, Liu MC, Camargo CAJr. (2009). Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004. Arch Intern Med, 169: 626-632
{{custom_citation.content}}
|
[28] |
Genuis SJ, Schwalfenberg GK, Hiltz MN, Vaselenak SA (2009). Vitamin D status of clinical practice populations at higher latitudes: analysis and applications. Int J Environ Res Public Health, 6: 151-173
{{custom_citation.content}}
|
[29] |
Oliveri B, Plantalech L, Bagur A, Wittich AC, Rovai G, Pusiol E, et al. (2004). High prevalence of vitamin D insufficiency in healthy elderly people living at home in Argentina. Eur J Clin Nutr, 58: 337-342
{{custom_citation.content}}
|
[30] |
Burnand B, Sloutskis D, Gianoli F, Cornuz J, Rickenbach M, Paccaud F, et al. (1992). Serum 25-hydroxyvitamin D: distribution and determinants in the Swiss population. Am J Clin Nutr, 56: 537-542
{{custom_citation.content}}
|
[31] |
Flicker L, Mead K, MacInnis RJ, Nowson C, Scherer S, Stein MS, et al. (2003). Serum vitamin D and falls in older women in residential care in Australia. J Am Geriatr Soc, 51: 1533-1538
{{custom_citation.content}}
|
[32] |
Hashemipour S, Larijani B, Adibi H, Javadi E, Sedaghat M, Pajouhi M, et al. (2004). Vitamin D deficiency and causative factors in the population of Tehran. BMC Public Health, 4: 38
{{custom_citation.content}}
|
[33] |
Marwaha RK, Tandon N, Reddy DR, Aggarwal R, Singh R, Sawhney RC, et al. (2005). Vitamin D and bone mineral density status of healthy schoolchildren in northern India. Am J Clin Nutr, 82: 477-482
{{custom_citation.content}}
|
[34] |
Daniels ED, Pettifor JM, Schnitzler CM, Moodley GP, Zachen D (1997). Differences in mineral homeostasis, volumetric bone mass and femoral neck axis length in black and white South African women. Osteoporos Int, 7: 105-112
{{custom_citation.content}}
|
[35] |
Zhang Q, Xiao-Qi HU, Guo HX (2010). VITAMIN D NUTRITION STATUS IN CHINESE TIBETAN AND HAN NATIONALITY CHILDREN AND ADOLESCENTS. Modern Preventive Medicine, 37:465-467.
{{custom_citation.content}}
|
[36] |
Unger MD, Cuppari L, Titan SM, Magalhaes MC, Sassaki AL, dos Reis LM, et al. (2010). Vitamin D status in a sunny country: where has the sun gone? Clin Nutr, 29: 784-788
{{custom_citation.content}}
|
[37] |
Hammad LN, Abdelraouf SM, Hassanein FS, Mohamed WA, Schaalan MF (2013). Circulating IL-6, IL-17 and vitamin D in hepatocellular carcinoma: potential biomarkers for a more favorable prognosis? J Immunotoxicol, 10: 380-386
{{custom_citation.content}}
|
[38] |
Weinstein SJ, Mondul AM, Kopp W, Rager H, Virtamo J, Albanes D (2013). Circulating 25-hydroxyvitamin D, vitamin D-binding protein and risk of prostate cancer. Int J Cancer, 132: 2940-2947
{{custom_citation.content}}
|
[39] |
Mondul AM, Weinstein SJ, Virtamo J, Albanes D (2012). Influence of vitamin D binding protein on the association between circulating vitamin D and risk of bladder cancer. Br J Cancer, 107: 1589-1594
{{custom_citation.content}}
|
[40] |
Gregory KJ, Zhao B, Bielenberg DR, Dridi S, Wu J, Jiang W, et al. (2010). Vitamin D binding protein-macrophage activating factor directly inhibits proliferation, migration, and uPAR expression of prostate cancer cells. PLoS One, 5: e13428
{{custom_citation.content}}
|
[41] |
Gressner OA, Gao C, Siluschek M, Kim P, Gressner AM (2009). Inverse association between serum concentrations of actin-free vitamin D-binding protein and the histopathological extent of fibrogenic liver disease or hepatocellular carcinoma. Eur J Gastroenterol Hepatol, 21: 990-995
{{custom_citation.content}}
|
[42] |
Gorham ED, Garland CF, Garland FC, Grant WB, Mohr SB, Lipkin M, et al. (2005). Vitamin D and prevention of colorectal cancer. J Steroid Biochem Mol Biol, 97: 179-194
{{custom_citation.content}}
|
[43] |
Giovannucci E, Liu Y, Rimm EB, Hollis BW, Fuchs CS, Stampfer MJ, et al. (2006). Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst, 98: 451-459
{{custom_citation.content}}
|
[44] |
Ahonen MH, Tenkanen L, Teppo L, Hakama M, Tuohimaa P (2000). Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control, 11: 847-852
{{custom_citation.content}}
|
[45] |
Feskanich D, Ma J, Fuchs CS, Kirkner GJ, Hankinson SE, Hollis BW, et al. (2004). Plasma vitamin D metabolites and risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev, 13:1502-1508
{{custom_citation.content}}
|
[46] |
Garland CF, Garland FC, Gorham ED, Lipkin M, Newmark H, Mohr SB, et al. (2006). The role of vitamin D in cancer prevention. Am J Public Health, 96: 252-261
{{custom_citation.content}}
|
[47] |
Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP (2007). Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr, 85: 1586-1591
{{custom_citation.content}}
|
[48] |
Lavie CJ, Dinicolantonio JJ, Milani RV, O'Keefe JH (2013). Vitamin D and cardiovascular health. Circulation, 128: 2404-2406
{{custom_citation.content}}
|
[49] |
Ferder M, Inserra F, Manucha W, Ferder L (2013). The world pandemic of vitamin D deficiency could possibly be explained by cellular inflammatory response activity induced by the renin-angiotensin system. Am J Physiol Cell Physiol, 304: C1027-1039
{{custom_citation.content}}
|
[50] |
Somjen D, Weisman Y, Kohen F, Gayer B, Limor R, Sharon O, et al. (2005). 25-hydroxyvitamin D3-1alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation, 111: 1666-1671
{{custom_citation.content}}
|
[51] |
Fernandes dA, D. A. (2009). Vitamin D, a neuro-immunomodulator: Implications for neurodegenerative and autoimmune diseases. Psychoneuroendocrinology, 34 Suppl 1: S265-S277
{{custom_citation.content}}
|
[52] |
Stumpf WE (2012). Drugs in the brain--cellular imaging with receptor microscopic autoradiography. Prog Histochem Cytochem, 47: 1-26
{{custom_citation.content}}
|
[53] |
Norman PE, Powell JT (2014). Vitamin D and cardiovascular disease. Circ Res, 114: 379-393
{{custom_citation.content}}
|
[54] |
Borges AC, Feres T, Vianna LM, Paiva TB (1999). Effect of cholecalciferol treatment on the relaxant responses of spontaneously hypertensive rat arteries to acetylcholine. Hypertension, 34: 897-901
{{custom_citation.content}}
|
[55] |
Uberti F, Lattuada D, Morsanuto V, Nava U, Bolis G, Vacca G, et al. (2014). Vitamin D protects human endothelial cells from oxidative stress through the autophagic and survival pathways. J Clin Endocrinol Metab, 99: 1367-1374
{{custom_citation.content}}
|
[56] |
Polidoro L, Properzi G, Marampon F, Gravina GL, Festuccia C, Di Cesare E, et al. (2013). Vitamin D protects human endothelial cells from H(2)O(2) oxidant injury through the Mek/Erk-Sirt1 axis activation. J Cardiovasc Transl Res, 6: 221-231
{{custom_citation.content}}
|
[57] |
Carvalho LS, Sposito AC (2015). Vitamin D for the prevention of cardiovascular disease: Are we ready for that? Atherosclerosis, 241: 729-740
{{custom_citation.content}}
|
[58] |
Talmor Y, Bernheim J, Klein O, Green J, Rashid G (2008). Calcitriol blunts pro-atherosclerotic parameters through NFkappaB and p38 in vitro. Eur J Clin Invest, 38: 548-554
{{custom_citation.content}}
|
[59] |
Ohsawa M, Koyama T, Yamamoto K, Hirosawa S, Kamei S, Kamiyama R (2000). 1alpha,25-dihydroxyvitamin D(3) and its potent synthetic analogs downregulate tissue factor and upregulate thrombomodulin expression in monocytic cells, counteracting the effects of tumor necrosis factor and oxidized LDL. Circulation, 102: 2867-2872
{{custom_citation.content}}
|
[60] |
Brewer LC, Michos ED, Reis JP (2011). Vitamin D in atherosclerosis, vascular disease, and endothelial function. Curr Drug Targets, 12: 54-60
{{custom_citation.content}}
|
[61] |
Pilz S, Gaksch M, O'Hartaigh B, Tomaschitz A, Marz W (2013). The role of vitamin D deficiency in cardiovascular disease: where do we stand in 2013? Arch Toxicol, 87: 2083-2103
{{custom_citation.content}}
|
[62] |
Oh J, Riek AE, Darwech I, Funai K, Shao J, Chin K, et al. (2015). Deletion of macrophage Vitamin D receptor promotes insulin resistance and monocyte cholesterol transport to accelerate atherosclerosis in mice. Cell Rep, 10: 1872-1886
{{custom_citation.content}}
|
[63] |
Harinarayan CV (2014). Vitamin D and diabetes mellitus. Hormones (Athens), 13: 163-181
{{custom_citation.content}}
|
[64] |
Lim S, Kim MJ, Choi SH, Shin CS, Park KS, Jang HC, et al. (2013). Association of vitamin D deficiency with incidence of type 2 diabetes in high-risk Asian subjects. Am J Clin Nutr, 97: 524-530
{{custom_citation.content}}
|
[65] |
Vimaleswaran KS, Berry DJ, Lu C, Tikkanen E, Pilz S, Hiraki LT, et al. (2013). Causal relationship between obesity and vitamin D status: bi-directional Mendelian randomization analysis of multiple cohorts. PLoS Med, 10: e1001383
{{custom_citation.content}}
|
[66] |
Al-Timimi DJ, Ali AF (2013). Serum 25(OH) D in Diabetes Mellitus Type 2: Relation to Glycaemic Control. J Clin Diaqn Res, 7: 2686-2688
{{custom_citation.content}}
|
[67] |
Baeke F, Gysemans C, Korf H, Mathieu C (2010). Vitamin D insufficiency: implications for the immune system. Pediatr Nephrol, 25: 1597-1606
{{custom_citation.content}}
|
[68] |
Cheng Q, Li YC, Boucher BJ, Leung PS (2011). A novel role for vitamin D: modulation of expression and function of the local renin-angiotensin system in mouse pancreatic islets. Diabetologia, 54: 2077-2081
{{custom_citation.content}}
|
[69] |
Kadowaki S, Norman AW (1984). Dietary vitamin D is essential for normal insulin secretion from the perfused rat pancreas. J Clin Invest, 73: 759-766
{{custom_citation.content}}
|
[70] |
Redecker P, Cetin Y (1997). Rodent pancreatic islet cells contain the calcium-binding proteins calcineurin and calretinin. Histochem Cell Biol, 108: 133-139
{{custom_citation.content}}
|
[71] |
Bourlon PM, Faure-Dussert A, Billaudel B, Sutter BC, Tramu G, Thomasset M (1996). Relationship between calbindin-D28K levels in the A and B cells of the rat endocrine pancreas and the secretion of insulin and glucagon: influence of vitamin D3 deficiency and 1,25-dihydroxyvitamin D3. J Endocrinol, 148: 223-232
{{custom_citation.content}}
|
[72] |
Jeffery LE, Qureshi OS, Gardner D, Hou TZ, Briggs Z, Soskic B, et al. (2015). Vitamin D Antagonises the Suppressive Effect of Inflammatory Cytokines on CTLA-4 Expression and Regulatory Function. PLoS One, 10: e0131539
{{custom_citation.content}}
|
[73] |
Moreira TS, Hamadeh MJ (2010). The role of vitamin D deficiency in the pathogenesis of type 2 diabetes mellitus. E-SPEN, the European e-Journal of Clinical Nutrition and Metabolism, 5: e155-e165
{{custom_citation.content}}
|
[74] |
Rigby WF, Denome S, Fanger MW (1987). Regulation of lymphokine production and human T lymphocyte activation by 1,25-dihydroxyvitamin D3. Specific inhibition at the level of messenger RNA. J Clin Invest, 79: 1659-1664
{{custom_citation.content}}
|
[75] |
Martineau AR, Wilkinson KA, Newton SM, Floto RA, Norman AW, Skolimowska K, et al. (2007). IFN-gamma- and TNF-independent vitamin D-inducible human suppression of mycobacteria: the role of cathelicidin LL-37. J Immunol, 178: 7190-7198
{{custom_citation.content}}
|
[76] |
Almerighi C, Sinistro A, Cavazza A, Ciaprini C, Rocchi G, Bergamini A (2009). 1Alpha,25-dihydroxyvitamin D3 inhibits CD40L-induced pro-inflammatory and immunomodulatory activity in human monocytes. Cytokine, 45: 190-197
{{custom_citation.content}}
|
[77] |
Chen S, Sims GP, Chen XX, Gu YY, Chen S, Lipsky PE (2007). Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol, 179: 1634-1647
{{custom_citation.content}}
|
[78] |
Harms LR, Burne TH, Eyles DW, McGrath JJ (2011). Vitamin D and the brain. Best Pract Res Clin Endocrinol Metab, 25: 657-669
{{custom_citation.content}}
|
[79] |
Kesby JP, Eyles DW, Burne TH, McGrath JJ (2011). The effects of vitamin D on brain development and adult brain function. Mol Cell Endocrinol, 347: 121-127
{{custom_citation.content}}
|
[80] |
Bertone-Johnson ER, Powers SI, Spangler L, Brunner RL, Michael YL, Larson JC, et al. (2011). Vitamin D intake from foods and supplements and depressive symptoms in a diverse population of older women. Am J Clin Nutr, 94: 1104-1112
{{custom_citation.content}}
|
[81] |
Hoogendijk WJ, Lips P, Dik MG, Deeg DJ, Beekman AT, Penninx BW (2008). Depression is associated with decreased 25-hydroxyvitamin D and increased parathyroid hormone levels in older adults. Arch Gen Psychiatry, 65: 508-512
{{custom_citation.content}}
|
[82] |
Jorde R, Sneve M, Figenschau Y, Svartberg J, Waterloo K (2008). Effects of vitamin D supplementation on symptoms of depression in overweight and obese subjects: randomized double blind trial. J Inetrn Med, 264: 599-609
{{custom_citation.content}}
|
[83] |
Annweiler C, Llewellyn DJ, Beauchet O (2013). Low serum vitamin D concentrations in Alzheimer's disease: a systematic review and meta-analysis. J Alzheimers Dis, 33: 659-674
{{custom_citation.content}}
|
[84] |
Hollo A, Clemens Z, Kamondi A, Lakatos P, Szucs A (2012). Correction of vitamin D deficiency improves seizure control in epilepsy: a pilot study. Epilepsy Behav, 24: 131-133
{{custom_citation.content}}
|
[85] |
Wilkins CH, Sheline YI, Roe CM, Birge SJ, Morris JC (2006). Vitamin D deficiency is associated with low mood and worse cognitive performance in older adults. Am J Geriatr Psychiatry, 14: 1032-1040
{{custom_citation.content}}
|
[86] |
Llewellyn DJ, Lang IA, Langa KM, Muniz-Terrera G, Phillips CL, Cherubini A, et al. (2010). Vitamin D and risk of cognitive decline in elderly persons. Arch Intern Med, 170: 1135-1141
{{custom_citation.content}}
|
[87] |
Eyles DW, Smith S, Kinobe R, Hewison M, McGrath JJ (2005). Distribution of the vitamin D receptor and 1 alpha-hydroxylase in human brain. J Chem Neuroanat, 29: 21-30
{{custom_citation.content}}
|
[88] |
Jande SS, Maler L, Lawson DE (1981). Immunohistochemical mapping of vitamin D-dependent calcium-binding protein in brain. Nature, 294: 765-767
{{custom_citation.content}}
|
[89] |
Partonen T (1998). Vitamin D and serotonin in winter. Med Hypotheses, 51: 267-268
{{custom_citation.content}}
|
[90] |
Masoumi A, Goldenson B, Ghirmai S, Avagyan H, Zaghi J, Abel K, et al. (2009). 1alpha,25-dihydroxyvitamin D3 interacts with curcuminoids to stimulate amyloid-beta clearance by macrophages of Alzheimer's disease patients. J Alzheimers Dis, 17: 703-717
{{custom_citation.content}}
|
[91] |
Buell JS, Dawson-Hughes B, Scott TM, Weiner DE, Dallal GE, Qui WQ, et al. (2010). 25-Hydroxyvitamin D, dementia, and cerebrovascular pathology in elders receiving home services. Neurology, 74: 18-26
{{custom_citation.content}}
|
[92] |
Perez-Lopez FR (2007). Vitamin D and its implications for musculoskeletal health in women: an update. Maturitas, 58: 117-137
{{custom_citation.content}}
|
[93] |
Looker AC, Mussolino ME (2008). Serum 25-hydroxyvitamin D and hip fracture risk in older U.S. white adults. J Bone Miner Res, 23: 143-150
{{custom_citation.content}}
|
[94] |
Adams JS, Hewison M (2008). Unexpected actions of vitamin D: new perspectives on the regulation of innate and adaptive immunity. Nat Clin Pract Endocrinol Metab, 4: 80-90
{{custom_citation.content}}
|
[95] |
Abramovitch S, Dahan-Bachar L, Sharvit E, Weisman Y, Ben Tov A, Brazowski E, et al. (2011). Vitamin D inhibits proliferation and profibrotic marker expression in hepatic stellate cells and decreases thioacetamide-induced liver fibrosis in rats. Gut, 60: 1728-1737
{{custom_citation.content}}
|
[96] |
Neeman R, Abramovitch S, Sharvit E, Elad-Sfadia G, Haklai R, Kloog Y, et al. (2014). Vitamin D and S-farnesylthiosalicylic acid have a synergistic effect on hepatic stellate cells proliferation. Dig Dis Sci, 59: 2462-2469
{{custom_citation.content}}
|
[97] |
Petta S, Camma C, Scazzone C, Tripodo C, Di Marco V, Bono A, et al. (2010). Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology, 51: 1158-1167
{{custom_citation.content}}
|
[98] |
Lange CM, Bojunga J, Ramos-Lopez E, von Wagner M, Hassler A, Vermehren J, et al. (2011). Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. J Hepatol, 54: 887-893
{{custom_citation.content}}
|
[99] |
Choudhary NS, Tomar M, Chawla YK, Bhadada SK, Khandelwal N, Dhiman RK, et al. (2011). Hepatic osteodystrophy is common in patients with noncholestatic liver disease. Dig Dis Sci, 56: 3323-3327
{{custom_citation.content}}
|
[100] |
Targher G, Bertolini L, Scala L, Cigolini M, Zenari L, Falezza G, et al. (2007). Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis, 17: 517-524
{{custom_citation.content}}
|
[101] |
Embry AF, Snowdon LR, Vieth R (2000). Vitamin D and seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol, 48: 271-272
{{custom_citation.content}}
|
[102] |
Guenther L, Van de Kerkhof PC, Snellman E, Kragballe K, Chu AC, Tegner E, et al. (2002). Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol, 147: 316-323
{{custom_citation.content}}
|
[103] |
Sanghi D, Mishra A, Sharma AC, Singh A, Natu SM, Agarwal S, et al. (2013). Does vitamin D improve osteoarthritis of the knee: a randomized controlled pilot trial. Clin Orthop Relat Res, 471: 3556-3562
{{custom_citation.content}}
|
[104] |
Nakagawa Y, Koizumi M, Fukagawa M (2015). Current Topics on Vitamin D. Vitamin D and chronic kidney disease. Clin Calcium, 25: 413-423
{{custom_citation.content}}
|
{{custom_ref.label}} |
{{custom_citation.content}}
|
/
〈 | 〉 |